DFO
TGTX icon

Duquesne Family Office’s TG Therapeutics TGTX Stock Holding History

Duquesne Family Office’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-280,000
Closed -$4.26M – 86
2024
Q1 		$4.26M Buy
+280,000
New +$4.46M 0.1% 67

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Duquesne Family Office's TGTX Position: Q2 2024 in Review

Duquesne Family Office sold out of TG Therapeutics (TGTX) in Q2 2024, closing a stake of 280,000 shares — an estimated $4.26M sold.

Duquesne Family Office first reported a position in TGTX in Q1 2024 and held it in 1 quarter. The position peaked at $4.26M in Q1 2024. 259 funds tracked by Wall St. Rank hold TGTX as of Q2 2024.

  • Duquesne Family Office reported no remaining TG Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Duquesne Family Office sold 280,000 TG Therapeutics shares in Q2 2024, an estimated $4.26M.
  • Duquesne Family Office first reported a position in TG Therapeutics in Q1 2024 and held it in 1 quarter.
  • Duquesne Family Office's TG Therapeutics position peaked at $4.26M in Q1 2024.
  • 259 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2024.

Based on Duquesne Family Office's 13F filing for Q2 2024, filed 14 Aug 2024.